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Abstract
In contrary to the common belief that only one strand of the pre-
miRNA is active (usually the 5p one that is the more abundant) while
the second one (miRNA*) is discarded, functional 5p and 3p have been
observed for many miRNAs. Among those miRNAs is miR-34a which
is a target gene of the tumor suppressor p53. In this paper we have
re-examined the role of miR-34a-5p and miR-34a-3p in the signaling
pathway of p53. We found that they target overlapping sets of genes
(MDM2 and THBS1). By a GO enrichment analysis we found that
THBS1 is involved in cancer and metastasis relevant processes. We
have also deduce that p53, MDM2 and miR-34a are linked by a type
1 incoherent FFL that represent a novel mechanism for accelerating
the response of p53 to external stress signals.
1 Introduction
p53 has been dubbed ”guardian of the genome” [1] or gatekeeper [2]
due to its central role in maintaining the genomic stability and tu-
mor suppression [3, 4, 5]. It has been found to be mutated in about
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half of the human cancers [6, 7]. Since its discovery p53 has been
subject to a tremendous amount of work making it one of the most
extensively studied gene. Its tumor suppressive role consists in induc-
ing anti-proliferative cellular responses to a variety of stress signals,
namely a cell-cycle arrest, senescence or an apoptosis. p53 can then
be activated in response to DNA damage, hypoxia, or aberrant growth
signals resulting from deregulated expression of oncogenes [8, 9, 10].
Under normal conditions p53 is expressed at low level as a result of the
action of the ubiquitin-protein ligase MDM2, that repress p53 through
ubiquitin-mediated degradation [11, 12]. In response to a stress sig-
nal as DNA damage p53 undergoes post-transcriptional modifications
(phosphorylation and acetylation) by various kinases, including ATM,
ATR, DNA-PK, Chk1, and Chk2 [13]. These modifications activate
p53 by inhibiting MDM2 from binding to its N-terminal and allow it
to carry out its major function as a transcription factor that binds
to specific DNA sequences and activate the transcription of adjacent
genes. By inducing the expression of its target genes p53 induces
cell-cycle arrest or apoptosis.
MicroRNAs (miRNAs) are small (20 25 nucleotides) non-coding
RNAs that negatively regulate gene expression post transcriptionally
by base-pairing to the 3’UTR of target mRNAs leading to repression of
protein production or mRNA degradation (For a recent introduction
see for example [14]). a single miRNA can target hundreds of different
mRNAs, and a single mRNA can be coordinately suppressed by multi-
ple different miRNAs, They are involved in many biological processes,
in particular cancer-relevant processes such as proliferation, cell cy-
cle control, apoptosis, differentiation, migration and metabolism. A
miRNA can have either oncogenic or tumor suppressive function. Ex-
amples of tumor suppressor miRNAs are let-7 family, miR-29, miR-34
and miR -15, and of oncogene miRNAs are miR-17-92, miR-155 and
miR-221.
The biogenesis of miRNAs can be summarized as follows: a pri-
mary transcript (pri-miRNA) is first generated by RNA polymerase
II as separate transcriptional units or embedded within the introns of
protein coding genes. Then the primary transcript is processed by the
microprocessor complex containing the RNase III enzyme Drosha to
an approximate 70-nucleotide (nt) pre-miRNA hairpin (the precursor-
miRNA) [15, 16, 17]. Pre-miRNAs are subsequently exported to the
cytoplasm by exportin 5 (XPO5) [18, 19] where their terminal loops
are excised by the RNase III Dicer to give rise to a double-stranded 22
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nt stem composed of 5’ and 3’ strands representing 5p and 3p respec-
tively. While one of the two strands (the passenger strand miRNA*)
is discarded, the other one (the guide) miRNA is then embeded into
the RISC (RNA Induced Silencing Complex) to complementary target
mRNA for post-transcriptional gene silencing [20].
Since it was believed that according to the thermodynamic stability
of the pre-miRNA cells preferentially select the less stable one of the
two strands (the guide) and destroy the other one (the miRNA*),
early works miRNAs have focused on the guide strand (which was
usually considered as the 5p one because it was found to be more
abundant than its counterpart miRNA* in humans [21]). However,
even though miRNA* are less abundant they are often present and
remain functional because they conserve their seed sequences and have
been isolated from RISC [22, 23] . It has been shown by profiling
analyses that both strands could be co-accumulated in some tissues
while being subjected to strand selection in others [24, 25, 26]. The
interplay between the 5p and 3p strands from the same precursor
has been shown either in arm-switching where the dominant miRNA
is switched from one arm of the precursor to the other [27] or by
targeting overlapping sets of genes when the abundances of the two
strands are similar [28]. Functional 5p and 3p have been characterized
for many miRNAs. Examples include miR-9 [29], miR-17 [30], miR-19
[23], miR-28 [31], miR-30c [32], miR-125a [33], miR-142 [34], miR-155
[35], miR-199 [36, 37], miR-223 [38], miR-342 [39], miR-2015 [40],
miR-18a [41], and miR-582 [42]. In some cases the two arms function
in opposing ways (e.g. miR-28 [31] and miR-125 [33]), while in others
they function in joint fashion (e.g. miR-199 [37] and miR-155 [35]).
miRNAs have been shown to be important components in the p53
network Their interactions with p53 have been demonstrated through
the identification of several miRNAs as direct target genes of p53.
By inducing the expression of specific miRNAs that have a tumor
suppressive function a novel mechanism for tumor suppression for p53
has been then revealed. In particular the role of the miR-34 family
has been reported in several studies [43].
In mammalians miR-34 family consists of miR-34a, miR-34b and
miR-34c, that are encoded by two different genes. miR-34a is en-
coded by an individual transcript in chromosome 1 and expressed in a
majority of tissues, while miR-34b and miR-34c share a common pri-
mary transcript in chromosome 11 and are mainly expressed in lung
tissues. Several studies have reported that the members of miR-34
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family were direct target genes of p53 and their upregulation induces
apoptosis and cell-cycle arrest. [44, 45, 46, 47, 48, 49, 50]. Indeed,
Ectopic expression of miR-34 induces cell cycle arrest in both primary
and tumour-derived cell lines [50]. Inactivation of miR-34a strongly
attenuates p53-mediated apoptosis in cells exposed to genotoxic stress
[46]. mir-34b/mir-34c were also down-regulated in p53-null human
ovarian carcinoma cells and both cooperate in suppressing prolifera-
tion of neoplastic epithelial ovarian cells [45]. Since cell-cycle arrest
and apoptosis are the responses of p53 to the stress signals, these facts
imply that miR-34 mediate the tumor suppressive function of p53. On
the other hand the members of the miR-34 family can have decreased
expression in cancer because of the inactivating mutations of p53 or
the expression of viral inhibitors of p53, but also as a consequence of
their own mutational or epigenetic inactivation.
Since 30% of all genes and the majrity of the genetic pathways are
regulated by miRNAs [51, 52, 53], we can expect some miRNAs to reg-
ulate p53 and its pathway. This hypothesis has been verified and some
miRNAs have been identified as regulators of p53. miR-504 can nega-
tively regulate p53 expression through its binding to two binding sites
in human p53 3-UTR [54]. It has also been reported that miR-125b
is another miRNA targeting p53 [55]. Another regulator is miR-29
that was identified as a positive regulator of p53 that up-regulate p53
protein levels and induce p53-mediated apoptosis through repression
of p85 [56]. Furthermore, miR-34a, which is a transcription target of
the p53 protein, was also found to positively regulate p53 activity and
function in apoptosis through its direct negative regulation of SIRT1
[57]. SIRT1 is a negative regulator of p53, which physically interacts
with p53 and deacetylates Lys382 of p53 [58].
The purpose of this paper is the study of the role of both miR-
34a-5p and miR-34a-3p in the signaling pathway of the p53.
2 Materiels and methods
We begin by using DIANA-miRPath v3. 0 which is a miRNA pathway
analysis web-server, providing accurate statistics utilizing predicted or
experimentally validated miRNA interactions derived from DIANA-
TarBase [59]. We first perform a KEGG reverse search for miRNAs
in the p53 signaling pathway (—hsa04115) by choosing the TarBase v
7.0 for method. In the same web-server we obtain the target genes of
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the different miRNAs that we found. The distribution of the target
genes in the pathway can also be displayed.
Then we use the cytoscape 3.4.0 software to visualize the interac-
tions where the relevant genes are involved. We take the intAct 1 .
to be our source of interactions. We filter by taxonomy identifier to
restrict the obtained network to the human case. In order to form
clusters of genes that share a similar function we use the clusterMaker
a Cytoscape application with the GLay Community Clustering algo-
rithm. the BiNGO a Cytoscape Plugin [60] gives the Gene Ontology
(GO) terms that are significantly overrepresented in each cluster.
3 Results and discussion
The result of the KEGG reverse search was a list containing 660 differ-
ent miRNAs including hsa-miR-34a-5p (p-value = 1.840530e-100) and
hsa-miR-34a-3p (p-value = 4.325757e-5). The respective p-values can
be interpreted as expressing the fact that 5p is more abundant than
3p. The list of target genes contains 30 genes for miR-34a-5p and
two for miR-34a-3p (MDM2 and THBS1) that are also target genes of
the miR-34a-5p. The involvement of these genes in the p53 signaling
pathway is shown in figure 1.
THBS1
By loading the list of the 30 target genes of miR-34a-5p (containing
also the two targets of miR-34a-3p) in Cytoscape 3.4.0 and searching
the interaction in IntAct we obtain a network composed of 2492 nodes
and 6493 edges. After clustering this network by the clusterMaker
application we obtain the result shown in figure 2 where the cluster
containing THBS1 was highlighted, This cluster is shown in figure 3.
In order to find the pathways in which the THBS1 gene is involved
we use the BINGO application of Cytoscape, and the relevant GO
terms that are overexpressed in the corresponding cluster are given in
table 1
1IntAct is one of the largest available repositories for curated molecular interactions
data, storing PPIs as well as interactions involving other molecules. It is hosted by the
European Bioinformatics Institute. IntAct has evolved into a multisource curation plat-
form and many other databases curate into IntAct and make their data available through
it [23].
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Figure 1: The signaling pathway of p53 with the target genes of miR-34-
5p/3p highlighted
Figure 2: The result of the clustering of the initial network representing
different interactions of the target genes of miR-34a-5p/3p
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Figure 3: The cluster representing THBS1 and its interactions
GO terms overexpressed p-value
Regulation of response to external stimulus 2.34× 10−6
Regulation of response to stress 3.09× 10−6
Regulation of cell adhesion 6.29× 10−4
Positive regulation of apoptosis 5.48× 10−3
Negative regulation of cell-matrix adhesion 3.07× 10−3
Induction of apoptosis 1.42× 10−3
Negative regulation of angiogenesis 6.48× 10−3
Table 1: GO term enrichment for the THBS1
7
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miR-34a
MDM2
Figure 4: Type 1 incoherent FFL composed of p53, miR-34a and MDM2
According to this analysis we can deduce that the THBS1 gene is
involved in regulating tumor suppression processes. But it is also clear
that it contributes to some anti metastatic pathways like angiogenesis
and cell adhesion.
MDM2
As was mentioned in the introduction MDM2 and p53 are linked by
a negative feedback loop. However, since MDM2 is a target gene of
miR-34a which means that it is negatively regulated by this miRNA,
we can represent the interaction between the three molecules (p53,
MDM2 and miR-34a) as a Feed Forward Loop (FFL). According to
the signs of the three interactions (activation/repression) the present
loop is a type 1 incoherent FFL (figure 4).
The dynamics of this FFL can be described as follows: when p53
begins to accumulate as a response to stress signals MDM2 first rises
since it is positively regulated by this gene. miR-34a is one of the
direct target genes of p53, thus, at some level of p53 the expression
of miR-34a begins also to increase, when it reaches some cellular level
MDM2 begins to decrease. It has been demonstrated that the response
time of the type 1 incoherent FFL is smaller than the one of a single
regulation system [61].
Thus in cases where speedy responses are needed this type of reg-
ulatory loop is more advantageous than the simple one. In our case
MDM2 is the principal cell antagonist of p53 that limits its anti growth
function in normal cells. Indeed, in unstressed cells p53 is present at
very low levels due to the continuous degradation by ubiquitination
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which is mediated by MDM2. In stressed cells, in order for p53 to ac-
cumulate in response to stress signals it has to escape the degradation
by MDM2. This is achieved by some protein kinases that phospho-
rylate its amino-terminal sites which are close to the MDM2 binding
regions of the protein, inhibiting the interaction between the two pro-
teins. on the other hand MDM2 itself is the product of p53-inducible
gene. Thus the two genes are linked by an autoregulatory negative
feedback loop ([62]and references therein). Thus the FFL constitute
an other mechanism that accelerates the stabilization of p53 in re-
sponse to external stimilus.
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